Bronchitol Deferred by Australian Pharmaceutical Advisory Committee
Release Date: 21/04/2011 12:00am
Pharmaxis today announced a delay to the listing of Bronchitol on the Australian Pharmaceutical Benefits Scheme (PBS). The company's first submission to list Bronchitol for the treatment of cystic fibrosis was reviewed at the March meeting of the Pharmaceutical Benefits Advisory Committee (PBAC) and was not recommended for inclusion in the PBS, at that time, due to what the PBAC described as “uncertainties in where Bronchitol will fit in clinical practice and consequent difficulties in identifying the right comparator in one clinical setting that leads to uncertain cost-effectiveness."
A resubmission has been prepared to address the issues raised by the PBAC and will be made at the earliest opportunity.
Categories: News and Media